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Abstract
Background: Quality indicators (QIs) are an important tool for improving clinical practice and are increasingly
being developed from evidence-based guideline recommendations. We aimed to identify, select and apply
guideline recommendations to develop a set of QIs to measure the implementation of evidence-based practice
using routinely recorded clinical data in United Kingdom (UK) primary care.
Methods: We reviewed existing national clinical guidelines and QIs and used a four-stage consensus development
process to derive a set of ‘high impact’ QIs relevant to primary care based upon explicit prioritisation criteria. We
then field tested the QIs using remotely extracted, anonymised patient records from 89 randomly sampled primary
care practices in the Yorkshire region of England.
Results: Out of 2365 recommendations and QIs originally reviewed, we derived a set of 18 QIs (5 single, 13
composites – comprising 2–9 individual recommendations) for field testing. QIs predominantly addressed chronic
disease management, in particular diabetes, cardiovascular and renal disease, and included both processes and
outcomes of care. Field testing proved to be critical for further refinement and final selection.
Conclusions: We have demonstrated a rigorous and transparent methodology to develop a set of high impact,
evidence-based QIs for primary care from clinical guideline recommendations. While the development process was
successful in developing a limited set of QIs, it remains challenging to derive robust new QIs from clinical
guidelines in the absence of established systems for routine, structured recording of clinical care.
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Background
Clinical evidence that can cut avoidable deaths and
enhance quality of life does not reliably find its way into
everyday patient care. It is widely recognised that the
translation of evidence into practice is unpredictable and
can be a slow and haphazard process [1]. In the United
Kingdom, there are large geographical variations in the
level and quality of care in a range of clinical areas, in-
cluding diabetes, stroke and cancer; their magnitude
cannot easily be explained away by population and case
mix factors [2]. This gap between evidence and practice
is a strategically important problem for policy-makers,
healthcare systems and research funders because it limits
the health, social and economic impacts of clinical re-
search [3]. Limited resources inevitably mean that
quality improvement initiatives cannot focus on all clin-
ical guideline recommendations at once; clinicians need
to identify and prioritise those that have the potential
for the most positive impact for patients.
The primary care context presents particular imple-
mentation challenges not encountered in other settings –
given limited practice organisational capacity, increasing
complexity of care, and the dispersed and independent na-
ture of practices [4–6]. An international review of quality
of care studies from primary care concluded, “In almost
all studies reviewed the quality of care did not attain ac-
ceptable standards of practice” [7]. A number of initiatives
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in the UK are used to increase implementation of effective
practice in primary care. These include the development
and dissemination of evidence-based clinical guidelines by
the National Institute for Health and Care Excellence
(NICE) [8] and the use of financial incentives to reward
adherence to performance indicators set out in the Quality
and Outcomes Framework (QOF) [9].
Measuring adherence to recommended practice is a
cornerstone of any strategy to improve the quality of
care. Measurement is required to identify inappropriate
variations in practice, target improvement endeavours,
and monitor their impact. In the absence of such data,
implementation strategies are best-guess rather than
data-driven. The development of quality indicators (QIs)
from clinical guidelines offers a way to judge whether
recommended practice is being followed and thereby al-
lows the quality of care to be measured [10–12]. Formal
consensus methods [13] are generally used both to pri-
oritise those clinical guideline recommendations suitable
for QI development and also to develop valid and reli-
able QIs [12, 14].
However, several challenges and considerations need
to be balanced in the development and application of
QIs:
 Indicators developed solely by expert panels may be
“unoperationalisable, unreliable, too rare to be
useful, or too hard to extract reliably.” [15].
 Methods that depend upon manual data extraction
can be resource-intensive.
 The utility of routinely collected data drawn from
existing schemes, such as QOF, is limited by
incomplete coverage of health problems [16].
 Indicators focussing on health care processes should
have a strong evidence base showing that the care
process leads to improved outcomes, and recognise
that there may be a number of intervening steps
before an improved outcome is realised (for
example, the steps of adding in antihypertensive
medication, further monitoring blood tests as
required, and further blood pressure review) [17].
 Indicators focusing on processes of care rather
than health outcomes may not help overcome
therapeutic inertia, i.e. the failure to intensify
treatment in patients with an abnormal clinical
measurement [18].
 Those focusing on health outcomes are subject to
higher ‘noise to signal’ ratios, whereby a range of
factors beyond professional practice influence
outcomes [19–21].
Those leading and evaluating improvement strategies
in primary care also need to consider efficiency. Imple-
mentation studies generally focus on one clinical
condition. This has advantages, for example so that an
intervention to promote better detection of hypertension
complements another to improve the treatment of de-
tected hypertension. However, the impact and generalis-
ability of such studies is limited in a number of ways:
 Only a minority of single issue guideline
recommendations are relevant to primary care and
sufficiently clinically important to justify concerted
implementation and provide a high return to
investment ratio.
 Many important clinical practice recommendations
are not directly amenable to measurement.
 There are risks of encountering ‘ceiling effects’
where adherence to a given recommendation has
reached a point beyond which it is difficult to
improve practice further.
We recognise that family physicians are generalists
who already contend with a large number of QIs. We set
out to develop and prioritise indicators that were both
acceptable to physicians and likely to have the highest
impact on patient care and outcomes [14]. Therefore, as
part of a wider research programme (Action to Support
Practices Implementing Research Evidence; ASPIRE), we
identified and selected a range of what we term ‘high im-
pact’ clinical practice recommendations and developed a
limited set of QIs for UK primary care. ASPIRE ultimately
aims to develop and undertake a randomised evaluation of
the effects of implementation packages targeting high
impact recommendations. We focused on evidence-based
recommendations with greatest potential for improving
quality of care and which could potentially be measured
using routinely recorded data.
Methods
We screened existing UK (NICE) clinical guideline rec-
ommendations and UK clinical primary care (QOF) indi-
cators and used a four-stage consensus development
process to identify those relevant to primary care based
upon: burden of illness; potential for significant patient
benefit; scope for improvement upon current levels of
adherence; likelihood of cost savings without patient
harm; feasibility of measuring adherence; and, the extent
to which following a recommendation is directly within
the control of individual practice teams or professionals
[22]. We then developed QIs based on these recommen-
dations or recommendation composites and undertook
field-testing using routinely collected primary care prac-
tice data.
Stage 1: initial screening
We identified candidate recommendations and indica-
tors from three sources: all NICE clinical guidelines
Rushforth et al. BMC Family Practice  (2015) 16:156 Page 2 of 10
published from December 2002 to June 2012; all NICE
Quality Standards published from June 2010 to June
2012; and all QOF clinical domain indicators as at June
2012. (From this point on, we will use the term ‘recom-
mendations’ to also include ‘indicators’ whilst acknow-
ledging that indicators are phrased differently given that
they are measurement criteria.) One clinical researcher
(BR) initially screened titles or summaries of the NICE
guidelines and quality standards, excluding those relat-
ing exclusively to secondary care or those which had
been superseded by a more recent update. From NICE
guidelines, we extracted individual recommendations
listed in the ‘key priorities for implementation’ from
each guideline, together with the full set of recommen-
dations from 16 guidelines judged particularly relevant
to primary care (e.g. diagnosis and management of
hypertension) (Additional file 1).
Two researchers (BR & RF) independently screened
the resulting list of recommendations. We removed
those judged irrelevant to primary care (e.g. ‘Decontam-
inate the skin at the insertion site with chlorhexidine
gluconate in 70 % alcohol before inserting a peripheral
vascular access device or a peripherally inserted central
catheter’ [23]) or not measurable using routine data (e.g.
‘Healthcare professionals should adopt a consulting style
that enables the child, young person or adult with epi-
lepsy, and their family and/or carers as appropriate, to
participate as partners in all decisions about their health-
care, and take fully into account their race, culture and
any specific needs’ [24]). Sets of recommendations that
were clearly linked to one another were grouped to form
‘composite’ recommendations (e.g. the nine recommended
processes of care for patients with Type 2 diabetes [25]).
We included recommendations judged to have potential
for significant patient benefit either individually or as part
of a composite with others. Disagreements were resolved
through discussion.
Stage 2: online shortlisting by consensus panel
We convened a consensus panel comprising 11 mem-
bers: five family physicians, including two with responsi-
bilities for commissioning healthcare services and
population health; one practice nurse; one practice man-
ager; one consultant clinical advisor from NICE accre-
dited in public health; one health informatics specialist;
and two patient representatives, one from a patient sup-
port and advocacy group and another with a role in
commissioning. Whilst aiming for diversity, we deliber-
ately weighted the panel towards primary care clinicians
usually targeted by clinical practice recommendations; a
number of judgements required an in-depth, tacit under-
standing of the day-to-day realities of clinical practice,
e.g. knowledge of contraindications and need for moni-
toring when initiating beta-blockers for heart failure. We
opted for 11 participants because a review of consensus
development techniques indicated that we would
gain relatively little in reliability by exceeding this
number [13].
We conducted an online rating process whereby
panellists rated each recommendation from Stage 1 ac-
cording to three criteria: burden of illness (e.g. preva-
lence, severity, costs); potential for significant patient
benefit (e.g. longevity, quality of life, safety of care); and
scope for improvement upon current levels of adherence
(e.g. from perceived current low levels or high varia-
tions). We instructed panellists to rate all recommenda-
tions on a 9-point Likert scale (where one is low and
nine is high) according to their perceptions of current
practice. Although patient representatives were encour-
aged to rate each recommendation, a ‘don’t know’ option
was available if they felt unable to do so for this and sub-
sequent stages. We piloted this process with three family
physicians and two lay people beforehand and responded
by clarifying instructions and briefing each panellist indi-
vidually before the rating process. We analysed median
scores for each rating using Excel and SPSS (version 19).
We ranked recommendations according to the com-
bined scores for burden of illness and patient benefit
and also only retained those recommendations rated five
or more on the ‘scope for improvement’ criterion. We
aimed to apply a cut-off that would result in around 50
recommendations reaching the next stage.
Stage 3: face-to-face consensus panel meeting
We used a modified RAND process, which is useful for
judgements requiring deliberation and discussion [13].
First, panellists independently completed an additional
online survey and rated the recommendations resulting
from Stage 2 on a 9-point Likert scale according to three
criteria: feasibility of measuring adherence (e.g. from
clinical data routinely collected for QOF); extent to
which following a recommendation is directly within the
control of individual practice teams or professionals;
and, the likelihood of cost savings without patient harm.
Panellists next attended a facilitated and structured
face-to-face meeting. We presented median ratings for
each recommendation. We focused discussion on
those with maximal discordance, defined as at least
three panellists scoring a recommendation 1–3 and at
least three scoring it 7–9. Panellists had the opportun-
ity to view summaries of the strength of evidence for
each recommendation, clarify aspects of recommenda-
tions, and discuss reasons for low or high rankings.
Panellists independently rated each recommendation
again immediately after discussing each, taking into ac-
count panel deliberations and their own and aggregate
initial ratings. We aimed to take the 20 top-rated rec-
ommendations forward for further development based
Rushforth et al. BMC Family Practice  (2015) 16:156 Page 3 of 10
upon the median ratings from Stage 2 and revised rat-
ings from Stage 3.
Stage 4: Informal sense-checking
We added this further stage after reviewing the Stage 3
rankings for two reasons. First, we were struck by unex-
pected rankings which appeared to lack face validity
when considered against our criteria. For example, we
had doubts about the feasibility of using routinely avail-
able data to measure adherence on recommended sec-
ondary prevention following myocardial infarction:
‘Advice on physical activity should involve a discussion
about current and past activity levels and preferences.
The benefit of exercise may be enhanced by tailored ad-
vice from a suitably qualified professional’ [26]. Second,
we were planning to take selected high impact recom-
mendations forward to develop and evaluate interven-
tions to support their implementation. Hence, we
wanted to ensure that selected recommendations were
likely to be consistent with local priorities whilst their
measurement was unlikely to face ceiling effects given
known national and local initiatives.
We therefore identified a convenience sample of four
family physician commissioning leads and six academic
family physicians with whom we had existing working
relationships and who had practical experience of meas-
uring primary care outcomes. We asked them to review
the full ranked list of recommendations from Stage 2, se-
lect between five and 10 recommendations that they
considered would best meet our aims and highlight any
they considered problematic to target. We then collated
their selections and written comments. The research
team drew upon this further feedback in discussions to
finalise our selected high impact recommendations.
Stage 5: Field testing
We randomly sampled and wrote to 114 general prac-
tices in West Yorkshire which used the SystmOne™ elec-
tronic health record. We first asked practices for
consent to remote extraction of anonymised patient data
(‘opt in’). Following a period of three to four weeks, we
contacted practices again and asked them to inform us if
they objected to the data extraction (‘opt out’).
One clinical researcher (BR) then drafted an expanded
text for each recommendation, using logical operators
(e.g. ‘AND’ and ‘OR’) to link descriptive statements to
produce numerators and denominators which would
identify whether the element of care occurred or not.
Two other researchers (RF & TW) checked and
amended these as appropriate prior to testing. A data
analyst specialist (SF) took the numerators and denomi-
nators for each recommendation and generated search
algorithms within SystmOneTM. We then undertook an
iterative process of refinement of the search algorithms
in light of the test data generated and following further
input from two family physician advisors. For recom-
mendations that were from the QOF such as: ‘The per-
centage of patients with diabetes in whom the last blood
pressure is ≤ 140/80 mmHg’ [27], we utilised the existing
QOF business rules set [28], although the timeframe for
compliance for some recommendations was amended
e.g. from 15 to 12 months. The QI from the composite
recommendation on risky prescribing was constructed
by a data analyst specialist (SF) using the specification of
numerators and denominators by Dreischulte et al [29].
Ethical review
The study was approved by National Research Ethics
Service Committee Yorkshire and the Humber - Leeds
Central (12/YH/0254). The Committee favourably
reviewed the study, including the collection of anon-
ymised patient data for the field testing without individ-
ual consent.
Results
Stage 1
Out of 147 NICE clinical guidelines identified, we ex-
cluded 20 relating exclusively to secondary care and 20
which had been superseded by a more recent update
(Fig. 1). We extracted all recommendations from 16
guidelines judged particularly relevant to primary care
(Additional file 1). We identified 19 NICE Quality Stan-
dards, excluding four only relevant to secondary care,
and 95 QOF clinical indicators. Together, these sources
yielded a total of 2365 recommendations.
Screening of individual recommendations for relevance
to primary care, patient benefit, and amenability to meas-
urement yielded a total of 349 recommendations, 148 of
which we judged as potentially significantly beneficial to
patients and 201 as beneficial as part of a composite
group. We then agreed 56 single and 46 composite recom-
mendations respectively (Additional file 2).
Stage 2
Online panel ratings (Additional file 2) across all 102
recommendations and composites were generally high
for patient burden (mean ‘median’ score of 7.6; standard
deviation 0.68) and potential for patient benefit (7.8; SD
0.81), with lower scores for scope for improvement
(5.00; SD 0.88). We excluded 18 recommendations from
further review because they scored four or less on scope
for improvement (indicating that the panel perceived
adherence to these recommendations to be relatively
good). We then took forward 62 recommendations
(31 single and 31 composites) based upon the highest
aggregate rankings.
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Stage 3
The initial independent panel rating resulted in disagree-
ments (at least three panellists scoring a recommenda-
tion 1–3 and at least three scoring it 7–9) for 22
(11.8 %) ratings, with 20 concerning feasibility of meas-
uring adherence and two concerning the extent to which
following a recommendation is directly within the con-
trol of individual practice teams or professionals. Follow-
ing the panel meeting, there were disagreements for 12
(6.45 %) ratings. The mean ‘median’ ratings were: 6.8
(SD 1.57) for feasibility of measuring adherence, 7.2
(SD 0.76) for the extent to which following a recom-
mendation is directly within the control of individual
practice teams or professionals and 7.3 (SD 0.73) for
the likelihood of cost savings without patient harm.
Ratings for the 62 recommendations are shown in
Additional file 3.
Stage 4
As we had anticipated, comments from the subsequent
‘sense-checking’ exercise with family physicians mainly
concerned perceived likelihoods of ceiling effects, diffi-
culties in measurement or recommendations being out-
side the immediate control of the primary care team
(Additional file 3). We therefore excluded further rec-
ommendations following team discussion, e.g.
 ‘The percentage of patients with coronary heart
disease (CHD) who are currently treated with a
beta-blocker’ [27]. Judged at high risk of encountering
likely ceiling effect in patients who have had myocardial
infarctions; there are also credible recommended
alternatives in those with angina [30].
 ‘Cardiac rehabilitation should be equally accessible
and relevant to all patients after a myocardial
infarction (MI), particularly people from groups that
are less likely to access this service’ [26]. Considered
largely outside immediate control of primary care
teams.
 ‘Carry out tests [for ovarian cancer] in primary care
if a woman (especially if 50 or over) reports having
any of the following symptoms on a persistent or
frequent basis - particularly more than 12 times per
month: persistent abdominal distension; feeling full
and/or loss of appetite; pelvic or abdominal pain;
increased urinary urgency and/or frequency’ [31].
Considered too difficult to measure using routine data.
We amalgamated two similar recommendations (con-
cerning initiation of insulin in type 2 diabetes) and re-
placed one recommendation concerning prescribing
non-steroid anti-inflammatory drugs (NSAIDs) with a
composite recommendation on risky prescribing [29].
By the end of this process, we had derived a list of 18
Fig. 1 Flowchart of five stage recommendation selection and quality
indicator development process
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recommendations (Table 1), 11 of which had been
ranked in the top 20 by our panel, which mainly cov-
ered chronic disease management and cardiovascular
disease.
Stage 5
Out of 114 practices initially approached, four opted in
and seven refused; a further 15 opted out with our
second (‘opt out’) approach. One had closed, one had
merged with another in our sample and a third was
excluded due to their non-standard patient list. Our final
sample comprised 89 (78 %) practices.
Two worked examples of the initial stages of the QI
development process for recommendations are presented
in Fig. 2. The full set of SystmOne™ searches for each of
the 18 recommendations is available in Additional file 4.
Discussion
We developed a set of high impact QIs for primary care,
drawn from clinical guideline recommendations, which
can be measured using routinely collected data in UK
primary care. We included a systematic, four-stage con-
sensus process involving a multidisciplinary panel and
field tested selected indicators.
Our final set of 18 QIs was drawn from 2365 recom-
mendations and indicators; even allowing for duplica-
tions, our output demonstrates how much work is
needed to derive a set of high impact recommendations.
Other studies have also attempted to identify high im-
pact or highly relevant clinical guidelines recommenda-
tions for primary care from existing national clinical
guidelines and have similarly found this to be a labour
intensive process with limited ‘yield’ in terms of a final
set of recommendations highly relevant to primary care
[32]. Our final set of QIs with its focus on chronic dis-
ease management, overlaps with existing primary care
quality indicator sets [16, 33, 34] which also address
chronic conditions such as diabetes and cardiovascular
disease. We had intended that our work would lead to
the development of new QIs to complement those cur-
rently available in national indicator sets for primary
care in the UK, such as the QOF. However we found
that, in line with recent attempts to develop new QOF
indicators [35], our dependence on what can be ex-
tracted from routinely collected clinical data means that
few new QIs can be developed [36]; the existing data
sets are comprehensive in having developed most of the
indicators that can be measured in current UK primary
care computer systems.
There is an emerging consensus on methods of QI de-
velopment [12, 14, 37, 38]. Our work included key rec-
ommended processes. Although we did not undertake
separate systematic reviews of the evidence underpin-
ning each indicator, we drew almost exclusively upon
high-quality clinical guidelines [12] and shared summar-
ies of evidence with our panel. We used a four stage
consensus process, incorporating a modified RAND
process with a multidisciplinary panel [13], to derive a
set of QIs relevant to primary care based upon explicit
prioritisation criteria. We field tested and subsequently
refined our indicator set, an exercise undertaken for less
than half of the indicators identified in a systematic
review [12].
We draw attention to six limitations of our work,
mainly so that others can improve upon our methods.
First, our panel only explicitly discussed disagreements
Table 1 Final set of recommendations
Smoking: The percentage of patients in high risk groups whose notes
record smoking status and the offer of support and treatment within
preceding 15 months [composite].
Chronic Obstructive Pulmonary Disease (COPD): Diagnosis of COPD,
through use of spirometry and chest radiograph [composite].
Chronic Kidney Disease (CKD): The percentage of patients on the CKD
register with hypertension and proteinuria who are treated with an
ACE-inhibitor or angiotensin receptor blocker.
Chronic Kidney Disease (CKD): Measurement of blood pressure, urinary
protein excretion, and lifestyle advice [composite].
Chronic Kidney Disease (CKD): blood pressure and urinary protein
excretion targets, and appropriate drug therapy [composite].
Myocardial infarction (MI): All patients who have had an acute MI should
be offered specific combination drug treatment.
Chronic heart failure: Measurement of serum natriuretic peptides and
referral where appropriate [composite].
Atrial fibrillation (AF): recommendations concerning use of anti-coagulants
in AF [composite].
Hypertension: blood pressure targets in those under/over 80 years of
age [composite].
Hypertension: lifestyle advice and monitoring of cholesterol and urinary
protein excretion [composite].
Type 2 diabetes: 9 annual processes of care i.e. measurement of blood
pressure, lipids, renal function, urine albumin-creatinine ratio (ACR),
glycaemic control, BMI, smoking status, plus foot and eye checks
[composite].
Type 2 diabetes: Integrate dietary advice with a personalised diabetes
management plan.
Type 2 diabetes: Cardiovascular risk assessment and subsequent statin
therapy where indicated.
Type 2 diabetes: Achievement of target levels for blood pressure,
cholesterol and glycaemic control [composite].
Type 2 diabetes: For a person on dual therapy who is markedly
hyperglycaemic, consider starting insulin therapy in preference to
adding other drugs to control blood glucose.
Diabetes mellitus: The percentage of patients with diabetes in whom
the last blood pressure is ≤ 140/80 mmHg.
Non-steroidal anti-inflammatory drugs (NSAIDs): Use of NSAIDs and
monitoring of potential side-effects [composite].
Depression in adults: Recommendations concerning severity-appropriate
treatment of depression [composite].
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Fig. 2 Worked examples of initial stages of quality indicator development process
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on three types of rating criteria (feasible to measure;
under control of individual practice teams or profes-
sionals; and potential for cost savings without harm),
after they had initially screened a larger list on patient
burden, potential for patient benefit, and room for im-
provement. Anticipating the need to prioritise panellists’
time, we focused their discussion on the former criteria
that we considered would require higher degrees of
judgment. It is worth noting that there was a disagree-
ment level of only 7.5 % in the first survey (23 disagree-
ments from 306 ratings), with all but one focusing on
rating ‘room for improvement’. This low level of dis-
agreement suggests that although an initial round of rat-
ings is likely to achieve sufficient consensus, a second
round is important to clarify opinion on more difficult
ratings. It is also important to decide a priori whether
increased weighting should be given to certain compo-
nents which are judged to be of greater importance as
weighted criteria may have affected the Stage 3 outcome.
Within the current study, feasibility of measurement was
a key concern – however, this was given equal weight to
all other criteria. A post-hoc analysis with ‘feasibility’
double-weighted only made a limited difference to the
rankings, but this is an issue which should be considered
in future consensus processes of this type.
Second, our process lost a degree of transparency
through inclusion of an unstructured and relatively in-
formal Stage 4, whereby we ‘sense-checked’ our panel
outputs with a wider group of academic and commis-
sioning family physicians. The need to add this stage
somewhat highlights a relative failure of our preceding
consensus process to scrutinise the candidate indicators
within their limited time and experience. Panels de-
veloping indicators, even those including generalists,
may tend to over-estimate the feasibility of data col-
lection [36].
Third, our final set of criteria is skewed towards bio-
markers (e.g. glycaemic control in diabetes) used for
chronic disease monitoring. We recognise the risk of
marginalising holistic medical care through focusing at-
tention on what is measurable and what is not necessar-
ily important to patients or physicians [39]. However, as
well as including patient representatives in our consen-
sus process, we also sought to maintain a focus on rec-
ommendations supported by evidence of benefits for
patient and population outcomes (e.g. smoking cessa-
tion). We would welcome further work to develop
evidence-based indicators of holistic care for which phy-
sicians would reliably record data.
Fourth, our approach to developing high impact in-
dicators prioritised those associated with higher popu-
lation burdens of illness. One critique is that this
approach is prejudicial to rare diseases for which ap-
propriate care could make a major difference to
individual outcomes [38]. We recognise that we made
a trade-off here.
Fifth, we did not directly assess the reliability of data
recording. However, many of our measures were derived
from data which had either been through reliability
checks during piloting or were QOF indicators [40].
Sixth, the detailed operationalization of our indicators
is only relevant to UK primary care. Nevertheless, their
evidence base and basic structures should be transferable
to similar primary care settings.
One key implication of our work is that using clinical
guideline recommendations to develop QIs for use in
primary care is likely to lead to an indicator set that fo-
cuses predominantly on chronic disease management of
a range of single important diseases (cardiovascular dis-
ease, diabetes, chronic kidney disease). The current ab-
sence of clinical guideline recommendations for patients
with multi-morbidity [41] means that we have not been
able to consider the development of indicators that
measure the quality of care for this group of patients.
Clinical evidence and subsequent guidance continue to
evolve; Shekelle et al suggest that, as a general rule, guide-
lines should be re-evaluated for potential updating no less
frequently than every three years [42]. We therefore agree
with Stelfox and Straus that indicator development should
be an ongoing process to reflect important changes [37].
For example, we are presently re-examining our indicators
for atrial fibrillation in light of updated guidance, essen-
tially indicating that anticoagulation treatment, after tak-
ing bleeding risk into account, has become the expected
standard of medical care [43].
Our multi-disciplinary panel included both profes-
sional and patient representatives; Kotter et al found that
patient participation during QI development is ex-
tremely uncommon [12]. We were uncertain as to
whether patient representatives would be able to engage
in the ratings of complex recommendations. We re-
peated our analyses on identifying the numbers of dis-
agreements in the stage 3 survey (feasibility, control and
cost-saving) with, and without patient representatives.
Average median ratings across all criteria did not change
with the inclusion of patient representatives, suggesting
that patient opinions on these criteria did not markedly
differ from those of the professional panellists.
Conclusion
We have demonstrated that it is feasible to develop a se-
lected set of high impact QIs for primary care. Our de-
velopment process required considerable filtering of
existing guidelines and is highly dependent upon the
availability of routinely recorded data. Our methods
were also more iterative and required more judgment
than we had originally planned, especially considering
our additional sense checking stage and refinements
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following field testing. We will report practice perform-
ance against this set of QIs separately. Future work will
focus on a subset of these indicators which we will use
as outcome measures in a cluster randomised evaluation
of strategies to improve professional practice.
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